Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Cabaletta Bio, Inc. (CABA)
Company Research
Source: GlobeNewswire
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Tuesday, March 5, 2024 at 12:50 p.m. ET in Boston, MA. Members of management will also be available for one-on-one meetings. Jefferies Biotech on the Bay Summit: Members of management will be available for one-on-one meetings on Tuesday, March 12, 2024 in Miami, FL. A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (Nasdaq: CABA) is a clinical-sta
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
CABA
Earnings
- 3/21/24 - Miss
CABA
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- CABA's page on the SEC website